Thyroid Nodules in Type 2 Diabetes Mellitus

Abstract

The present analysis aims to investigate the prevalence of thyroid nodules in type 2 diabetes mellitus (T2DM) population. We searched PubMed, EMBASE, and Web of Science from inception to the March 1, 2018. The studies were selected to estimate the prevalence of thyroid nodules in T2DM subjects and to compare the prevalence of thyroid nodules in different glucose tolerance status. The random effects model was used, and the outcome was presented as a pooled prevalence proportion with 95% confidence interval (95% CI) or a summary odds ratio (OR) with 95% CI. In the end, 9 studies met the inclusion criteria and were included in the analysis. The pooled prevalence of thyroid nodules was 60% (95% CI: 0.52, 0.68) for T2DM 2 diabetes patients, 50% (95% CI: 0.48, 0.51) for pre-diabetes, and 43% (95% CI: 0.34, 0.52) for normal glucose tolerance population. Compared with patients without diabetes, diabetes subjects are more likely to develop thyroid nodules, adjusted OR for thyroid nodule was 1.78 (95% CI: 1.25, 2.55). Insulin resistance might be involved in thyroid nodule development.

Keywords

thyroid nodule / diabetes / insulin resistance

References

[1] HageM, ZantoutMS, AzarST. Thyroid disorders and diabetes mellitus. J Thyroid Res, 2011, 2011: 439463

[2] PeppaM, KoliakiC, NikolopoulosP, et al.. Skeletal muscle insulin resistance in endocrine disease. J Biomed Biotechnol, 2010, 2010: 527850

[3] DuntasLH, OrgiazziJ, BrabantG. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf), 2011, 75(1): 1-9

[4] HanC, HeX, XiaX, et al.. Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One, 2015, 10(8): e0135233

[5] GierachM, GierachJ, JunikR. Insulin resistance and thyroid disorders. Endokrynol Pol, 2014, 65(1): 70-76

[6] HanC, XiaX, LiuA, et al.. Circulating Betatrophin Is Increased in Patients with Overt and Subclinical Hypothyroidism. Biomed Res Int, 2016, 2016: 5090852

[7] AgbahtK, ErdoganMF, EmralR, et al.. Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism. Endocrine, 2014, 45(1): 106-113

[8] MiyauchiS, MatsuuraB, UedaT, et al.. Interleukin-18 induces insulin resistance in the hyperthyroid state. Endocr J, 2013, 60(4): 449-455

[9] WangC. The Relationship between Type 2 Diabetes Mellitus and Related Thyroid Diseases. J Diabetes Res, 2013, 2013: 390534

[10] KadiyalaR, PeterR, OkosiemeOE. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract, 2010, 64(8): 1130-1139

[11] RaiS, KumarJ K, et al.. Thyroid function in type 2 diabetes mellitus and in diabetic nephropathy. J Clin Diagn Res, 2013, 7(8): 1583-1585

[12] SomwaruLL, ArnoldAM, JoshiN, et al.. High frequency of and factors associated with thyroid hormone over-replacement and under-replacement in men and women aged 65 and over. J Clin Endocrinol Metab, 2009, 94(4): 1342-1345

[13] GharibH, PapiniE. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am, 2007, 36(3): 707-735

[14] AyturkS, GursoyA, KutA, et al.. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol, 2009, 161(4): 599-605

[15] RezzonicoJ, RezzonicoM, PusiolE, et al.. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid, 2008, 18(4): 461-464

[16] JunikR, KozinskiM D-, KozinskaK. Thyroid ultrasound in diabetic patients without overt thyroid disease. Acta Radiologica, 2006, 47(7): 687-691

[17] AnilC, AkkurtA, AyturkS, et al.. Impaired glucose metabolism is a risk factor for increased thyroid volume and nodule prevalence in a mild-to-moderate iodine deficient area. Metabolism, 2013, 62(7): 970-975

[18] StroupDF, BerlinJA, MortonSC, et al.. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. fJAMA, 2000, 283(15): 2008-2012

[19] LiuY, LiuJ, ZhangT, et al.. Type 2 diabetes mellitus associated with thyroid nodules: a longitudinal health check-up cohort study. J Shandong Univ (Chinese), 2015, 53(8): 83-86

[20] HuangXQ, ZhangHA, HuangQ. Correlation analysis between type 2 diabetes mellitus and thyroid nodules in elderly patients. Dier Junyi Daxue Xuebao (Chinese), 2015, 36(2): 221-225

[21] IttermannT, MarkusMR, SchipfS, et al.. Metformin inhibits goitrogenous effects of type 2 diabetes. Eur J Endocrinol, 2013, 169(1): 9-15

[22] GuoH, SunM, HeW, et al.. The prevalence of thyroid nodules and its relationship with metabolic parameters in a Chinese community-based population aged over 40 years. Endocrine, 2014, 45(2): 230-235

[23] TuW, ZhangG, YuS, et al.. Observations on factors that influence thyroid nodules in diabetic and non-diabetic patients in the Zhejiang province of China. Int J Clin Exp Med, 2015, 8(10): 19332-19338

[24] ZhengL, YanW, KongY, et al.. An epidemiological study of risk factors of thyroid nodule and goiter in Chinese women. Int J Clin Exp Med, 2015, 8(7): 11379-11387

[25] TaoYH, BiFF, LiuGL. Analysis of the prevalence rate and risk factors of thyroid nodules in Tangshan City. Occupation Health (Chinese), 2014, 30(23): 3415-3417

[26] RezzonicoJN, RezzonicoM, PusiolE, et al.. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord, 2009, 7(4): 375-380

[27] IFG. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond), 2009, 118(5): 315-332

[28] JalvingM, GietemaJA, LefrandtJD, et al.. Metformin: taking away the candy for cancer?. Eur J Cancer, 2010, 46(13): 2369-2380

[29] SilberschmidtD, KrawiecL, BocaneraLV, et al.. Effect of the interaction of TSH and insulin on the stimulation of 2-deoxyglucose uptake in FRTL-5 cells. J Endocrinol Invest, 1999, 22(7): 499-502

[30] BlancquaertS, WangL, PaternotS, et al.. cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol, 2010, 24(7): 1453-1468

[31] SantistebanP, AcebronA, Polycarpou-SchwarzM, et al.. Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol, 1992, 6(8): 1310-1317

[32] RapoportB, ChazenbalkGD, JaumeJC, et al.. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev, 1998, 19(6): 673-716

[33] KimuraT V K A, GolsteinJ, et al.. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev, 2001, 22(5): 631-656

[34] RappK, SchroederJ, KlenkJ, et al.. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia, 2006, 49(5): 945-952

[35] InoueM, IwasakiM, OtaniT, et al.. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med, 2006, 166(17): 1871-1877

[36] BlancE, PonceC, BrodschiD, et al.. Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome. Metab Syndr Relat Disord, 2015, 13(5): 221-226

[37] SantosMC, LouzadaRA, SouzaEC, et al.. Diabetes mellitus increases reactive oxygen species production in the thyroid of male rats. Endocrinology, 2013, 154(3): 1361-1372

[38] GuariguataL, WhitingDR, HambletonI, et al.. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract, 2014, 103(2): 137-149